Drug Update 2025
Immunology continues to touch all of our lives as dermatologists. The research and development pipeline remains exciting into the year 2024. We have moved beyond the large-scale “biologics era” in psoriasis and atopic dermatitis. 2022-2023 (and beyond) was the year of the big “biosimilar switch”. We are seeing the development of increasingly “fine tuned” molecules for dermatology conditions, with some exciting new launches in Canada within the past year. JAK Inhibitors have officially been prescribed in our practices for two years now in atopic dermatitis. We now have good “real world” experience with these molecules. We saw the launch of the first JAK inhibitor for Alopecia Areata in late 2023, with a second receiving Health Canada Notice of Compliance in 2024. Conditions such as vitiligo, alopecia areata, hidradenitis suppurativa, prurigo nodularis have shifted into the focus for much of the new dermatology pharmaceutical industry research and development. We are seeing unique molecules focusing on the microbiome or with unique methods of delivery. This presentation will provide an overview on what dermatology drugs are new to the market, the status of current clinical trials and an overview of the current landscape in dermatology drug development.
Learning Objective:
A high-level overview of molecules in the dermatology research and development pipeline, and molecules new to the market.